| Code: MTA13062 | Publication Date: Jul 2026 |
The following is a data-backed list of the leading South Korea Pericarditis companies, compiled through 6Wresearch's proprietary research and validated by in-house industry analysts. These companies represent the key players shaping competition in the South Korea Pericarditis Industry, including Novartis Korea Co., Ltd., Sanofi-Aventis Korea Co., Ltd., and other established names.
For detailed forecasts, data tables, and competitive benchmarking,
Explore the full South Korea Pericarditis Industry.
| Company Name | Novartis Korea Co., Ltd. |
|---|---|
| Established Year | 1991 |
| Headquarters | Basel, Switzerland |
| Official Website | Click Here |
Novartis leads with extensive expertise in inflammatory signalling pathways, providing targeted therapies essential for managing pericardial inflammation.
| Company Name | Sanofi-Aventis Korea Co., Ltd. |
|---|---|
| Established Year | 1989 |
| Headquarters | Paris, France |
| Official Website | Click Here |
Sanofi maintains a robust presence by supplying high-efficacy anti-inflammatory agents and fostering innovation in long-term cardiovascular immunity management.
| Company Name | AstraZeneca Korea Co., Ltd. |
|---|---|
| Established Year | 1992 |
| Headquarters | Cambridge, United Kingdom |
| Official Website | Click Here |
AstraZeneca is recognized for its commitment to cardiovascular research and community-focused initiatives that improve systemic disease management.
| Company Name | Pfizer Korea Ltd. |
|---|---|
| Established Year | 1969 |
| Headquarters | New York, New York, United States |
| Official Website | Click Here |
Pfizer focuses on the supply of foundational anti-inflammatory and analgesic medications, serving as a pillar for first-line pericarditis treatment.
| Company Name | Bayer Korea Ltd. |
|---|---|
| Established Year | 1955 |
| Headquarters | Leverkusen, Germany |
| Official Website | Click Here |
Bayer specializes in advanced cardiovascular therapeutics, providing critical options for secondary management and symptom control.
| Company Name | Merck Korea Ltd. |
|---|---|
| Established Year | 1989 |
| Headquarters | Darmstadt, Germany |
| Official Website | Click Here |
Merck provides innovative pharmaceutical solutions and R&D support, integrated into standard protocols for addressing cardiac inflammation.
| Company Name | Bristol Myers Squibb (BMS) Korea |
|---|---|
| Established Year | 1995 |
| Headquarters | New York, New York, United States |
| Official Website | Click Here |
BMS is a cornerstone in the immuno-oncology and inflammatory sectors, offering high-efficacy agents that help modulate immune-driven pericardial reactions.
| Company Name | Eli Lilly and Company (Korea) Inc. |
|---|---|
| Established Year | 1996 |
| Headquarters | Indianapolis, Indiana, United States |
| Official Website | Click Here |
Lilly supports the market by supplying vital therapeutic alternatives for multi-line treatment regimens, focusing on patient-centric outcomes.
| Company Name | Amgen Korea Limited |
|---|---|
| Established Year | 2015 |
| Headquarters | Thousand Oaks, California, United States |
| Official Website | Click Here |
Amgen utilizes its biotechnology leadership to provide precision solutions for complex, recurrence-prone inflammatory conditions.
| Company Name | Hanmi Pharmaceutical Co., Ltd. |
|---|---|
| Established Year | 1973 |
| Headquarters | Seoul, South Korea |
| Official Website | Click Here |
Hanmi Pharmaceutical, a key local leader, provides critical drug delivery systems and localized manufacturing of specialized anti-inflammatory agents.